NASDAQ$FULC
Fulcrum Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported business highlights and financial results for the third quarter of 2020.
Fulcrum Therapeutics reported progress in their ReDUX4 trial and are on track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020. They also announced key appointments to the management team and reported a cash runway into 2Q 2022.
- ReDUX4 trial progressing with full data expected in 2Q 2021.
- On track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020.
- Cash runway into 2Q 2022.
- Key appointments to management team.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$1.85M
Forward guidance
Fulcrum Therapeutics expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro